IP Library Granted Patent US 8,193,159
Granted Patent B2
US 8,193,159 · App. 12/279,183 · Granted Jun 5, 2012

MCP-1 binding nucleic acids

Assignee: NOXXON Pharma AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,193,159
App. No.
12/279,183
Granted
Jun 5, 2012
Kind
B2
Abstract

The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.

Claims (16)

1. An L-nucleic acid that binds a chemokine, or a homolog of said L-nucleic acid, wherein said L-nucleic acid has the sequence of SEQ ID NO:37, and the homolog has homology to the sequence of SEQ ID NO:37 of at least 85%.

2. The L-nucleic acid of claim 1 , wherein said chemokine comprises MCP-1.

3. The L-nucleic acid of claim 1 , comprising a modification.

4. The L-nucleic acid of claim 3 , wherein said modification comprises a polyethylene glycol (PEG) molecule.

5. The L-nucleic acid of claim 4 , wherein said PEG is at the 5′ terminus of said L-nucleic acid or said homolog.

6. The L-nucleic acid of claim 4 , wherein said PEG is at the 3′ terminus of said L-nucleic acid or said homolog.

7. The L-nucleic acid of claim 4 , wherein said PEG is straight chain or branched.

8. The L-nucleic acid of claim 4 , wherein said PEG is from about 2 kD to about 200 kD.

9. The L-nucleic acid of claim 4 , wherein said PEG is from about 40 kD to about 120 kD.

10. The L-nucleic acid of claim 3 , further comprising a linker.

11. The L-nucleic acid of claim 3 , wherein said modification comprises a biotin.

12. The L-nucleic acid of claim 1 , further comprising a chemokine.

13. The L-nucleic acid of claim 12 , wherein the chemokine is selected from the group consisting of eotaxin, MCP-1 and MCP-2.

14. A method for detecting a chemokine comprising exposing a sample suspected of comprising a chemokine to the L-nucleic acid according to claim 1 and detecting a complex of said L-nucleic acid and said chemokine.

15. The method of claim 14 , wherein the chemokine is selected from the group consisting of eotaxin, MCP-1 and MCP-2.

16. The method of claim 14 , further comprising a reagent immobilized on a solid phase.

Assignments (5)
CHANGE OF NAME Recorded Jan 26, 2023
From: NOXXON PHARMA AG
To: TME PHARMA AG
Reel/Frame 062489/0829 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2020
From: KREOS CAPITAL IV (UK) LIMITED
To: NOXXON PHARMA AG
Reel/Frame 051757/0649 →
SECURITY INTEREST Recorded Apr 27, 2015
From: NOXXON PHARMA AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 035501/0893 →
SECURITY INTEREST Recorded Mar 13, 2014
From: NOXXON PHARMA AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 032422/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: PURSCHKE, WERNER; JAROSCH, FLORIAN; EULBERG, DIRK; KLUSSMANN, SVEN; BUCHNER, KLAUS; MAASCH, CHRISTIAN
To: NOXXON PHARMA AG
Reel/Frame 021981/0958 →
Priority Claims (2)
EP 06002935 · Feb 14, 2006 · regional
EP 06024202 · Nov 22, 2006 · regional
Continuity (1)
Related Publication 20100284961A1 · Nov 11, 2010